Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction
出版年份 2021 全文链接
标题
Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction
作者
关键词
-
出版物
EUROPEAN HEART JOURNAL
Volume 42, Issue 36, Pages 3741-3752
出版商
Oxford University Press (OUP)
发表日期
2021-07-17
DOI
10.1093/eurheartj/ehab499
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Urinary drug metabolite testing in chronic heart failure patients indicates high levels of adherence with life‐prolonging therapies
- (2021) Mark Sweeney et al. ESC Heart Failure
- Hypertension Canada’s 2020 Evidence Review and Guidelines for the Management of Resistant Hypertension
- (2020) Swapnil Hiremath et al. CANADIAN JOURNAL OF CARDIOLOGY
- Obesity and the paradox of mortality and heart failure hospitalization in heart failure with preserved ejection fraction
- (2020) Taher M. Mandviwala et al. INTERNATIONAL JOURNAL OF OBESITY
- Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan
- (2020) Senthil Selvaraj et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Adherence to prescribed medications in patients with heart failure – insights from liquid chromatography-tandem mass spectrometry-based urine analysis
- (2020) J Simpson et al. European Heart Journal-Cardiovascular Pharmacotherapy
- Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF
- (2020) Karola S. Jering et al. JACC-Heart Failure
- Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction
- (2020) Kota Suzuki et al. HYPERTENSION
- Managing hypertension in patients with heart failure
- (2019) Tripti Gupta et al. CURRENT OPINION IN CARDIOLOGY
- Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction
- (2019) Li Shen et al. EUROPEAN JOURNAL OF HEART FAILURE
- Hypertension and Heart Failure
- (2019) Jeremy Slivnick et al. Heart Failure Clinics
- Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
- (2019) Scott D. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Heart Failure with Preserved Ejection Fraction
- (2018) James D. Gladden et al. Annual Review of Medicine
- Comparison of Time-to-First Event and Recurrent Event Methods in Randomized Clinical Trials
- (2018) Brian Claggett et al. CIRCULATION
- Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial
- (2018) Scott D. Solomon et al. Circulation-Heart Failure
- The role of arterial hypertension in development heart failure with preserved ejection fraction: just a risk factor or something more?
- (2018) Marijana Tadic et al. HEART FAILURE REVIEWS
- Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure
- (2018) Kevin Damman et al. JACC-Heart Failure
- 2018 ESC/ESH Guidelines for the management of arterial hypertension
- (2018) Bryan Williams et al. EUROPEAN HEART JOURNAL
- Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association
- (2018) Robert M. Carey et al. HYPERTENSION
- The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study
- (2017) Roland E Schmieder et al. EUROPEAN HEART JOURNAL
- Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials
- (2017) John G F Cleland et al. EUROPEAN HEART JOURNAL
- Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic HypertensionNovelty and Significance
- (2017) Bryan Williams et al. HYPERTENSION
- The Effects of LCZ696 in Patients With Hypertension Compared With Angiotensin Receptor Blockers
- (2017) Yang Zhao et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
- Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction
- (2017) Scott D. Solomon et al. JACC-Heart Failure
- Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials
- (2015) Chirag Bavishi et al. EUROPEAN HEART JOURNAL
- Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
- (2015) Bryan Williams et al. LANCET
- High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis
- (2014) Maciej Tomaszewski et al. HEART
- Spironolactone for Heart Failure with Preserved Ejection Fraction
- (2014) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Prevalence and Prognosis of Resistant Hypertension in Patients with Heart Failure
- (2014) Chun-Na Jin et al. PLoS One
- Higher Natriuretic Peptide Levels Associate With a Favorable Adipose Tissue Distribution Profile
- (2013) Ian J. Neeland et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial
- (2012) Scott D Solomon et al. LANCET
- The paradox of low BNP levels in obesity
- (2011) Aldo Clerico et al. HEART FAILURE REVIEWS
- Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study
- (2010) Luis Miguel Ruilope et al. LANCET
- Heart Failure With Preserved Ejection Fraction
- (2008) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction
- (2008) Barry M. Massie et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More